Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusionEfficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematuritySYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence.Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion.The past, present, and future of exudative age-related macular degeneration treatment.Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF.[Current therapeutic options in retinopathy of prematurity].Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusionSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDTreatment of retinopathy of prematurity: a review of conventional and promising new therapeutic optionsComparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis.Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy.[VEGF inhibitors in vitreoretinal interventions].Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbitsComparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion.Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.Intravitreal bevacizumab alone or combined with macular laser photocoagulation for recurrent or persistent macular edema secondary to branch retinal vein occlusion.Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trialPreclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabKinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapyEffects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.Importance of Central Retinal Sensitivity for Prediction of Visual Acuity after Intravitreal Bevacizumb in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion.Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade.Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery.The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healingOptical coherence tomography characteristics of responses to intravitreal bevacizumab in idiopathic choroidal neovascularization.A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series.Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.Small Molecular-Sized Artesunate Attenuates Ocular Neovascularization via VEGFR2, PKCα, and PDGFR Targets.A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
P2860
Q24193614-5DBB4F4F-CA82-4A08-B9BB-6CA18234CCA0Q24194783-C675780C-F7DB-4744-B078-E476ABBAB0A5Q24195003-FE37981F-7CDF-4E6A-8E31-F1B1DFC5BEE6Q24234625-D42B8A41-36E4-4D0D-9985-6BBA4341B9B9Q24609568-C44E8E40-489B-4383-BFBA-7F005C7117CEQ30490738-9C68F45D-852C-4CB8-B7F4-F9F825A98A8DQ33786804-5911B197-490F-4C84-8B04-A92A7007AF09Q33993712-F129E2DD-238A-4B91-AF1D-0FC3711D3B76Q34161956-94B029FD-E443-480B-A634-085F0239BA68Q34364080-07704808-5B04-4F79-973E-A465FF211216Q34501395-17BB8C10-CDA9-4997-A2A9-50AE23B1C235Q34588134-5C6B3603-8BD7-4D72-B018-1E75FB402290Q34608306-FBE60764-F2A6-470C-ACD6-754C5F39326AQ34704214-E7D23251-FE03-4A14-8773-AEC8A9D0FCACQ34735711-121FF96E-05F4-44FB-BA9F-C14DEC97E0D1Q34952041-E4A56D62-9716-48D5-8B07-E47705D4103CQ34991648-92D99EF1-652E-4DB0-BD96-9218AAC32B47Q35015882-0E6187FF-9467-427A-88F1-81B7F55FA61AQ35098562-E729AB82-AEFC-4E93-85EA-C4D7687D9510Q35100891-42AF2E51-8C9A-4733-9926-AB604321A4FDQ35223263-BB206FB1-1154-43EE-8437-EBA849581999Q35224191-E10D789C-140B-423D-9912-D335F587D0BCQ35226694-57B153C7-73B1-491B-AB38-FB9B5FD5DC9DQ35631284-3D8281BD-297D-4D43-A56F-87393BB30AADQ35689732-6F163F54-2176-4BBE-86E3-019A9CB7202DQ35749002-B7E1C9CD-6542-4514-895F-5638DE36F221Q35925907-9BEC8D7E-0573-4352-B92C-B6333E142D61Q36013973-CBF764B9-4D85-4827-8C0B-74089BBA1E9AQ36096360-D168F022-008E-40CE-B8AE-98A628D6CECDQ36154521-386CC9D9-83AD-4FC7-A32D-7F1FE4EAE6EFQ36174993-1451E272-2D59-4E12-86F7-A322C51BD91BQ36342984-2A425583-D222-4A33-B4B4-D3162F294AB6Q36574090-21AC265A-A62B-4630-8808-7348475F3E71Q36601736-01FE6501-863A-478C-8D29-BACA06FC0CABQ36731129-2542ECCA-04CF-4C95-AFD4-2AC07DA5F5C1Q36858958-BC9174FD-34EF-4F56-89DD-222CA7EB696AQ36914264-EB60184D-FB58-41FE-B35F-D181FBA52FD0Q37133086-10BC27EB-E685-4BF5-9BAE-7A1604EF4ED2Q37144488-03E5F7D5-B254-4BD2-A4EF-2192B7EEF4EFQ37183169-8FB6D7C0-BD94-4119-911C-7860EF9B9EA6
P2860
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
type
label
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
prefLabel
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
P1476
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
P2093
Carsten H Meyer
Nicole Eter
P304
P356
10.1016/J.AJO.2008.05.036
P407
P577
2008-07-17T00:00:00Z